检索结果-南通市图书馆

Pharmacological methods for ovarian function and fertility preservation in women with cancer:A literature review

Oncology Research 2024年第8期32卷 1309-1322页

作者： ANA S.CVETANOVIC MATTEO LAMBERTINI KEVIN PUNIE GORANA G.MATOVINA BRKO NIKOLA D.ZIVKOVIC MAJA J.POPOVIC MARIJANA M.MILOVIC KOVACEVIC LAZAR S.POPOVIC Department for Oncology Medical Faculty NisUniversity of NisNis18000Serbia clinic of Oncology University Clinical Centre NisNis18000Serbia Department of Internal Medicine and Medical Sciences(DiMI) School of MedicineUniversity of GenovaGenova16100Italy Department of Medical Oncology U.O.C Clinica di Oncologia MedicaIRCCS Ospedale Policlinico San MartinoGenova16100Italy Department of General Medical Oncology and Multidisciplinary Breast Centre Leuven Cancer InstituteUniversity Hospitals LeuvenLeuven3001Belgium Department of Medical Oncology Oncology Institute of VojvodinaSremska Kamenica21208Serbia Department for Pathology Medical Faculty NisUniversity of NisNis18000Serbia Center for Pathology University Clinical Centre NisNis18000Serbia Faculty of Medicine University of Novi SadNovi Sad21000Serbia Department of Medical Oncology Institute of Oncology and Radiology SerbiaBelgrade11000Serbia

Oncofertility is an extremely signiﬁcant topic that is increasingly being discussed owing to increased evidence indicating that fertility preservation does not affect the treatment outcomes of patients with cancer but signiﬁcantly contributes to preserving life *** effect of chemotherapy can range from minimal effects to complete ovarian *** data are available on the effects of monoclonal antibodies and targeted therapies on the ovaries and *** ovarian suppression by administering a gonadotropin-releasing hormone agonist(GnRHa)during chemotherapy decreases the gonadotoxic effect of chemotherapy,thereby diminishing the chance of developing premature ovarian insufﬁciency(POI).At present,the concomitant administration of GnRH analogs during chemotherapy is the only accepted pharmacological method for preserving ovarian ***,most randomized studies on the effectiveness of luteinizing hormone-releasing hormone agonists during chemotherapy in preventing POI have been conducted in women with breast cancer,with a considerably small number of studies on patients with hematological ***,most randomized controlled trials on breast cancer have revealed a decrease in treatment-induced POI risk,regardless of the hormone receptor *** addition,studies on hematological malignancies have yielded negative results;nevertheless,theﬁndings must be interpreted with caution owing to numerous *** guidelines from the American Society of clinical Oncology and ESMO clinical Practice Guidelines recommend sperm,oocyte,and embryo cryopreservation as a standard practice and only offering GnRHa to patients when proven fertility preservation methods are not *** this manuscript,we present a comprehensive literature overview on the application of ovarian suppression with GnRHa during chemotherapy in patients with cancer by addressing preclinical and clinical data,as well as future perspectives in thisﬁeld

关键词： Gonadotropin-releasing hormone agonists(GnRHa) Fertility preservation Premature ovarian insufficiency(POI) Premenopausal patients

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Targeting triple-negative breast cancer:A clinical perspective

引用

Oncology Research 2023年第3期31卷 221-238页

作者： LAZAR S.POPOVIC GORANA MATOVINA-BRKO MAJA POPOVIC KEVIN PUNIE ANA CVETANOVIC MATTEO LAMBERTINI Department of Medical Oncology Oncology Institute of VojvodinaSremska KamenicaSerbia Faculty of Medicine University of Novi SadNovi SadSerbia Department of General Medical Oncology and Multidisciplinary Breast Centre Leuven Cancer InstituteUniversity Hospitals LeuvenLeuvenBelgium Department for Oncology Medical Faculty NisUniversity of NisNisSerbia clinic of Oncology Clinical Centre NisNisSerbia Department of Internal Medicine and Medical Sciences(DiMI) School of MedicineUniversity of GenovaGenovaItaly Department of Medical Oncology U.O.C Clinica di Oncologia MedicaIRCCS Ospedale Policlinico San MartinoGenovaItaly

Triple-negative breast cancer(TNBC)is a disease with often an aggressive course and a poor prognosis compared to other subtypes of breast *** accounts for approximately 10%–15%of all diagnosed breast cancer cases and represents a high unmet need in the *** to just a few years ago,chemotherapy was the only systemic treatment option for this subtype(1).To date,TNBC is considered a heterogeneous *** of the existing classifications is based on the analysis of mRNA expression in 587 TNBC cases,in which Lehman et *** six subtypes of TNBC as follows:two basal-like(BL1 and BL2)subtypes,a mesenchymal(M)subtype,a mesenchymal stem-like(MSL)subtype,an immunomodulatory(IM)subtype,and a luminal androgen receptor(LAR)subtype(2).Later studies have demonstrated that the IM and MSL subtypes do not correlate with independent subtypes but reflect background expression by dense infiltration of tumor-infiltrating lymphocytes(TILs)or stromal *** to this finding,the classification of TNBC has been revised into the following four subtypes:basal 1,basal 2,LAR,and mesenchymal subtypes(3).Over the last years,several new strategies have been investigated for the treatment of patients with *** them,immunotherapy,antibody drug conjugates,new chemotherapy agents,and targeted therapy have been and are currently being *** present article aims to provide an updated overview on the different treatment options that are now available or are still under investigation for patients with TNBC.

关键词： Triple-negative breast cancer Immunotherapy Antibody-drug conjugates Target therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

IDENTIFYING THE TARGETS FOR GLAU-COMA CARE

引用

国际眼科杂志 2003年第1期3卷 119-119页

作者： C.E.Traverso san martino ospedale eye clinic Italy

The intraocular pressure (IOP) of glaucoma patients has been a fundamental therapeutic target for over 100 years, however, it is only recently that rigorous clinical trials have demonstrated definitively that lowering IOP delays vision loss. The Advanced Glaucoma Intervention Study (2000), the Collaborative Initial Glaucoma Treatment Study (2001), and the Early

关键词：青光眼治疗目标神经保护视网膜神经节细胞 IOP

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

THE EX-PRESSTM MINIATURE GLAUCO-MA IMPLANT: LONG-TERM RESULTS

引用

国际眼科杂志 2003年第1期3卷 104-104页

作者： C.E.Traverso san martino ospedale eye clinic Italy

The Ex-PRESS (Optonol Ltd.) is a miniature stainless steel glaucoma implant with a 50-micron internal lumen. A single-center, open, non-comparative case series was performed to evaluate the safety and efficacy of the ... 详细信息

关键词：青光眼微型不锈钢埋植物 Ex-PRESS 长期疗效 IOP 评价

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

eye reflux:an ocular extraesophageal manifestation of gastric reflux

引用

International Journal of Ophthalmology(English edition) 2018年第9期11卷 1503-1507页

作者： Danilo Mazzacane Valerio Damiani Michela Silvestri Giorgio Ciprandi Pierfranco Marino Asst Pavia and Asst Melegnano and Martesana Pavia 27100Italy DMG Medical Department Pomezia 00071Italy Istituto Giannina Gaslini Genoa 16147Italy ospedale Policlinico san martino Genoa 16132Italy Dipartimento di Scienze della Salute Universita del MoliseCampobasso 86100Italy

AIM： To suspect laryngopharyngeal reflux（LPR） in patients with ocular surface disease（OSD）. METHODS： The present study evaluated a group of subjects with OSD assessing the Ocular Surface Disease Index（OSDI） and the Reflux Symptom Index（RSI） to detect patients with suspected LPR and define a possible relationship between ***： Two hundred and ninety subjects（175 females, mean age： 60.41±15.68y） were consecutively visited at ophthalmologist offices. One hundred and one（34%） patients had pathological RSI（〉13） and consequently a suspected ***： The current study shows that suspected LPR may be common（34%） in patients with OSD and a suspected LPR may be considered in OSD patients when RSI score is 〉13 and OSDI score is 〉42.

关键词： gastric reflux eye reflux ocular surface disease index reflux symptom score

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Inflammation in the anterior visual pathway in multiple sclerosis:what do the animal models teach us?

引用

Neuroimmunology and Neuroinflammation 2021年第3期8卷 185-202页

作者： Christian Cordano Claudia Ramos Sam Arnow Andrés Cruz-Herranz Caroline Guglielmetti MicheleIester Fabio Bandini UCSF Weill Institute for Neurosciences Department of NeurologyUniversity of CaliforniaSan FranciscoCA 94158USA Neurosciences Group of Antioquia School of MedicineUniversidad de AntioquiaMedellín050010Colombia Department of Physical Therapy and Rehabilitation Science University of CaliforniaSan Francisco-San FranciscoCA 94158USA Department of Neurosciences RehabilitationOphthalmologyGeneticsMaternal and Child Health(DiNOGMI)University of GenoaGenoa 16132Italy IRCCS ospedale Policlinico san martino Genoa 16132Italy Department of Neurology S.Paolo HospitalSavona 17100Italy

A provocative and overly reductive mantra is that"the back of the eye is the front of the brain".Retinal imaging techniques that take advantage of this"window"to the central nervous system can provide valuable information regarding injury to the nervous system with relative ease and with a limited burden to *** retina develops embryonically as part of the neuroectoderm,is made up principally of neurons and their supporting cells,and is synaptically tied to the central nervous system(CNS).This has led to significant interest in using retinal health as a biomarker for brain health-given the relatively limited accessibility of brain tissue in chronic neurodegenerative diseases that progress over *** retina is not truly part of the CNS,and as with much of brain imaging-the grounds for asserting the pathological specificity of retinal imaging is ***-based methods such as optical coherence tomography indirectly provide an opportunity to evaluate retinal neurodegeneration,while autopsy studies,histology and immunohistochemistry predominate as the methods that collect direct pathological *** understanding of pathological retinal lesions characteristic of demyelinating diseases,specifically diseases showing anterior visual pathway involvement,has grown significantly in recent ***,much of the underlying pathobiology of injury remain *** review aims to highlight the major pathological features of the retina in multiple sclerosis,and its most used animal models(experimental autoimmune encephalomyelitis and cuprizone),with a particular focus on n the role of inflammation.

关键词： Anterior visual pathway multiple sclerosis optical coherence tomography experimental autoimmune encephalomyelitis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

低密度脂蛋白受体和HMG-CoA还原酶在人类睑裂斑及原发性翼状胬肉中的高表达

引用

世界核心医学期刊文摘（眼科学分册） 2005年第4期1卷 39-39页

作者： Peiretti E. Dess S. Putzolu M. Fossarello M. 王媛 University eye clinic Ospedale San Giovanni di Dio Via Ospedale I- 09124 Cagliari Italy

PURPOSE. There is now increasing evidence that pterygium and pinguecula are tumorlike tissues and that cell growth and DNA replication are closely linked to cholesterol metabolism. In this study, the expression of two main genes correlated to cholesterol metabolism- namely, the low- density lipoprotein receptor (LDL- R) gene and the hydroxy- methylglutaryl- co- enzyme A- reductase (HMG- CoA- R) gene- were investigated in primary pterygium, pinguecula, and normal conjunctiva. METHODS. Pterygium, pinguecula, and normal conjunctiva samples were obtained from 30 eyes (50% men) at the time of surgery. Total RNA extracted from the specimens was subjected to semiquantitative reverse transcription- polymerase chain reaction (RT- PCR). Equal amounts of total RNA were reverse transcribed into cDNA. The cDNA was subsequently amplified by the PCR in the presence of specific primers for low- density lipoprotein receptor (LDL- R) and for hydroxymethylglutaryl coenzyme A reductase (HMG- CoA- R). RESULTS. Semiquantitative RT- PCR analysis revealed that the mRNA levels of LDL- R and HMG- CoA- R were increased in pterygia, compared with levels in both pingueculae and normal conjunctivae. Differences were statistically significant (P < 0.05), including pingueculae versus normal conjunctivae. CONCLUSIONS. This study indicates that pterygium and pinguecula have an altered metabolism of cholesterol- namely increased LDL- R and HMG- CoA- R mRNAs- as is characteristic of tumorlike tissues, and that the high expression of LDL receptors renders them amenable to be treated by photodynamic therapy with intravenously injected verteporfin.

关键词： HMG-CoA 睑裂斑原发性翼状胬肉还原酶主要基因胆固醇代谢肿瘤样光动力治疗静脉内注射维替泊芬

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

A MULTI -NATIONAL RETROSPECTIVE STUDY OF RESOURCE UTILIZATION AS-SOCIATED WITH GLAUCOMA DISEASE PROGRESSION IN EUROPE

引用

国际眼科杂志 2003年第1期3卷 32-32页

作者： C.E.Traverso S.Gandolfi S.P.Kelly The Glaucoma Outcomes Study Gr J.G.Walt P.Buchholz J.J.Doyle K.M.Amaya S.V.Kotak san martino ospedale Ospedale Maggiore ItalyBolton Hos-pitals NHS Trust UKAustria France Germany Italy and UKAllergan CA USAAllergan GermanyThe Analytica Group NY USAThe Analytica Group NY USAThe Analytica Group NY USA

Objectives: To conduct a multi-national retrospective chart review with the purposes of assessing resource utilization, progression, and costs associated with treating glaucoma in Europe. Methods: Patient chart data was reviewed to assign patients to all stages of glaucoma progression. The Bascom Palmer Glaucoma Staging System (GSS) was selected, as most adaptable because

关键词：欧洲青光眼资源利用研究进展多国别回顾性队列分析

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

First-line pazopanib in patients with advanced non-clear cell renal carcinoma:An Italian case series

引用

World Journal of clinical Oncology 2021年第11期12卷 1037-1046页

作者： Sebastiano Buti Melissa Bersanelli Francesco Massari Ugo De Giorgi Orazio Caffo Gaetano Aurilio Umberto Basso Giacomo Carteni Claudia Caserta Luca Galli Francesco Boccardo Giuseppe Procopio Gaetano Facchini Giuseppe Fornarini Alfredo Berruti Elena Fea Emanuele Naglieri Fausto Petrelli Roberto Iacovelli Camillo Porta Alessandra Mosca Medical Oncology Unit University Hospital of ParmaParma 43126Italy Medicine and Surgery Department University of ParmaParma 43126Italy Division of Oncology Policlinico Sant’Orsola-Malpighi HospitalBologna 40138Italy Department of Oncology IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori(I.R.S.T.)Meldola 47014Italy Department of Medical Oncology Santa Chiara HospitalTrento 38122Italy Department of Medical Oncology Division of Urogenital and Head and Neck TumoursEuropean Institute of Oncology IRCCSMilan 20141Italy Medical Oncology Unit 3 Istituto Oncologico Veneto IOV IRCCSCastelfranco VenetoPadova 31033Italy Division of Oncology Azienda Ospedaliera di Rilievo Nazionale A.CardarelliNapoli 80131Italy Medical Oncology Unit Azienda Ospedaliera S.MariaTerni 05100Italy Oncology Unit 2 University Hospital of PisaPisa 56126Italy Academic Unit of Medical Oncology IRCCS San Martino Polyclinic HospitalGenova 16132Italy Medical Oncology Genitourinary Section Fondazione IRCCS Istituto Nazionale Dei TumoriMilan 20133Italy Departmental Unit of clinical and Experimental Uro-Andrologic Oncology Istituto Nazionale Tumori IRCCS Fondazione G.PascaleNapoli 80131Italy Medical Oncology Unit Istituto di Ricovero e Cura a Carattere Scientifico(IRCCS)Ospedale Policlinico San MartinoGenova 16132Italy University of Brescia ASST-Spedali CiviliBresciaBrescia 25123Italy Medical Oncology Unit S Croce and Carle Teaching HospitalCuneo 12100Italy Division of Medical Oncology Istituto Tumori G Paolo IIIRCCSBari 70124Italy Medical Oncology Unit ASST Bergamo OvestTreviglioBergamo 24047Italy Medical Oncology Unit Fondazione Policlinico Universitario Agostino Gemelli IRCCSRome 00161Italy Division of Oncology AOU Consorziale Policlinico di BariBari 70124Italy Department of Biomedical Sciences and Human Oncology University of Bari"A.Moro"Bari 70124Italy Multidisciplinary Outpatient Oncology clinic Candiolo Cancer InstituteFPO-IRCCSCandioloTurin 10060Italy

BACKGROUND Non-clear cell(ncc)metastatic renal-cell carcinoma(RCC)has dismal results with standard systemic therapies and a generally worse prognosis when compared to its clear-cell *** systemic combination therapies have emerged for metastatic RCC(mRCC),but the pivotal phase III trials excluded patients with nccRCC,which constitute about 30%of metastatic RCC *** To provide a piece of real-life evidence on the use of pazopanib in this patient *** The present study is a multicenter retrospective observational analysis aiming to assess the activity,efficacy,and safety of pazopanib as first-line therapy for advanced nccRCC patients treated in a real-life *** Overall,48 patients were *** the median follow-up of 40.6 mo,the objective response rate was 27.1%,the disease control rate was 83.3%,and the median progression-free survival and overall survival were 12.3(95%confidence interval[CI]:3.6-20.9)and 27.7(95%CI:18.2-37.1)mo,*** 3 adverse events occurred in 20%of patients,and no grade 4 or 5 toxicities were *** Pazopanib should be considered as a good first-line option for metastatic RCC with variant histology.

关键词： Pazopanib Non-clear cell Kidney cancer Renal-cell carcinoma Variant histology Tyrosine kinase inhibitors

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：